{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-139146","form_type":"8-K","ticker":"RLAY","cik":"0001812364","company_name":"Relay Therapeutics, Inc.","filed_at":"2025-06-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.828466+00:00","generated_at":"2026-05-19T13:46:21.738523+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Relay Therapeutics appoints Claire Mazumdar to board; Jami Ruben resigns","bullets":["Jami Ruben resigned as Class III director and Audit Committee member effective June 8, 2025; no dispute or disagreement.","Claire Mazumdar, Ph.D., appointed as Class III director and Audit Committee chair effective June 9, 2025.","Dr. Mazumdar is founding CEO of Bicara Therapeutics (Nasdaq: BCAX), a clinical-stage oncology company.","She received an initial option to purchase 421,241 shares at $3.36/share, vesting monthly over three years.","Board determined Dr. Mazumdar is independent under Nasdaq listing standards."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-139146","json":"https://secwatch.observer/filing/0001193125-25-139146.json","markdown":"https://secwatch.observer/filing/0001193125-25-139146.md","text":"https://secwatch.observer/filing/0001193125-25-139146.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1812364/000119312525139146/0001193125-25-139146-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1812364/000119312525139146/d948938d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T13:46:21.738523+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7b4bd586a8","claim":"Claire Mazumdar was appointed as Class III Director at Relay Therapeutics, Inc..","evidence_excerpt":"On June 9, 2025, upon the recommendation of its Nominating and Corporate Governance Committee, the Board appointed Claire Mazumdar, Ph.D., MBA as a member of the Board, effective as of June 9, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1812364/000119312525139146/0001193125-25-139146-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class III Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}